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Abstract Prostaglandin E2 (PGE2), a derivative of arachi-
donic acid, has been identified as a tumorigenic factor in many
cancers in recent studies. Prostaglandin E synthase 2
(PTGES2) is an enzyme that in humans is encoded by the
PTGES2 gene located on chromosome 9, and it synthesizes
PGE2 in human cells. In our study, we selected 119 samples
from endometrial cancer patients, with 50 normal endometri-
um tissue samples as controls, in which we examined the
expression of PTGES2. Both immunohistochemistry (IHC)
and Western blot analyses demonstrated that synthase
PTGES2, which is required for PGE2 synthesis, was highly
expressed in endometrium cancer tissues compared with nor-
mal endometrium. Stable PTGES2-shRNA transfectants were
generated in Ishikawa and Hec-1B endometrial cancer cell
lines, and transfection efficiencies were confirmed by RT-
PCR andWestern blot analyses. We found that PGE2 promot-
ed proliferation and invasion of cells in Ishikawa and Hec-1B
cells by cell counting kit-8 tests (CCK8) and transwell assays,
respectively. PGE2 stimulation enhanced the expression of
SUMO-1, via PGE2 receptor subtype 4 (EP4). Further analy-
sis implicated the Wnt/β-catenin signaling pathway function
as the major mediator of EP4 and SUMO-1. The increase in
SUMO-1 activity prompted the SUMOlyation of target
proteins which may be involved in proliferation and invasion.
These findings suggest SUMO-1 and EP4 as two potential
targets for new therapeutic or prevention strategies for endo-
metrial cancers.
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Introduction
Endometrial cancer is the most common tumor of the female
reproductive system in developed countries [1]. In the US,
endometrial cancer results in about 8,590 death cases per year
[2], while in developing countries, such as China, the mortal-
ity incidence is approximately 7.44/105 people [3].
Prostaglandin E2 (PGE2) is the most abundant prostanoid
in the human body and exhibits the most versatile functions
ranging from reproduction to neuronal, metabolic, and im-
mune functions [4]. Secreted PGE2 acts in either an autocrine
or paracrine manner through its four cognate G protein-
coupled receptors, EP1 to EP4. Many studies have found
PGE2 associated with tumors of the colorectal organs, lung,
and breast [5–7]. In some before studies of our research teams,
we have found some cytokines high expressed in endometrial
cancers [8, 9], and PGE2 is one of them. Some previous stud-
ies have also suggested that PGE2 participates in tumorigen-
esis of endometrial cancers [10, 11]; however, the definite
effect and its detailed mechanisms are unclear, which pro-
motes us interest in PGE2.
Dynamic chromatin structure regulation by post-
translational protein modifications (PTPM) modulates the ac-
cessibility of DNA and consequently the transcription of
genes. Small ubiquitin-like modifier (SUMO) modification
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in the epigenetic regulation of chromatin states has been ex-
tensively studied [12]. SUMOlyation of specific transcription
factors or chromatin remodeling proteins, in most cases, is
associated with repressive complex formation and a silencing
role in transcription regulation [13, 14]. In humans, three main
subtypes of SUMOs have been identified: SUMO-1, SUMO-
2, and SUMO-3 [15]. SUMO-1 is a highly conserved modifier
that can covalently conjugate to a variety of cellular proteins
[16–18]. One obvious function of SUMO-1 is its capability to
modify p53 and enhance transcriptional activity [19]. As p53
is often mutated in endometrial cancer, the likelihood that
SUMO-1 has an important role in endometrial cancers is high.
Herein, we examined the expression and effect of PGE2 on
endometrial cancer cells. This study investigated the role of
PGE2, via its receptor EP4, in the promotion of SUMO-1
expression, and identified that this regulation occurs through
Wnt/β-catenin signaling pathway, resulting in the enhance-
ment of proliferation and invasion of endometrial cancer cells.
Materials and methods
Reagents and antibodies
Prostaglandin E2 was from Sigma (St. Louis, MO).
Sulprostone (Sulp) was from ABCAM (Cambridge, UK).
Butaprost (Buta) was from Santa Cruz Biotechnology
(Dallas, USA). Prostaglandin E1 Alcohol (POH), L161982,
AZD5363, FH535, and ICI 182780 (ICI) were from Cayman
Chemical (Detroit, USA). Antibody of prostaglandin E syn-
thase 2 (Anti-PTGES2) was from Proteintech (Chicago,
USA). Antibodies of prostaglandin E receptor 4 (Anti-EP4),
SUMO-1, and SUMO-2, 3 were from ABCAM (Cambridge,
UK). ELISA Kit for Prostaglandin E2 (PGE2) was from
Cloud-Clone Corp (Houston, USA).
Patients and samples
Tissues samples for immunohistochemistry (IHC) and west-
ern blot were obtained from 119 patients with endometrial
cancer and 50 patients with normal endometrium who
underwent surgical resection at Shanghai General Hospital
from 2005 to 2014. The project was approved by the Human
Investigation Ethics Committee of the Shanghai General
Hospital, and informed consent was obtained from all patients
before the study.
Cell lines and culture conditions
The human endometrial Ishikawa cell lines were obtained
from Dr. Qi Che (Shanghai Jiao Tong University, Shanghai,
China). Ishikawa cells were grown in DMEM/F12 (Gibco,
Auckland, NZ) supplemented with 10 % fetal bovine serum
(FBS) (Gibco, Carlsbad, CA). Cells were incubated at 37 °C
in a humidified atmosphere containing 5 % CO2. All experi-
ments were performed at the third passage after thawing.
Total RNA extraction, real-time RT-PCR
Total RNA from Ishikawa cells was isolated by Trizol (15596-
026, Invitrogen) and cDNA as prepared using the reverse
transcriptase kit. Real-time reverse transcription (RT)-PCR
was conducted using an ABI Prism 7500 sequence detection
system (Applied Biosystems, Foster City, CA) and performed
with SYBR Green PCR Master Mix (Toyobo, Osaka, Japan).
A comparative CT method was used to analyze the relative
changes in gene expression. The results were expressed rela-
tive to the number of GAPDH transcripts (internal control).
Sequences of the primer pairs used are listed in Table 1.
Western blot
For Western blot analysis, cells were lysed in lysis buffer for
30 min at 4 °C. Total proteins were fractionated by SDS–
PAGE and transferred onto PVDF membrane. The mem-
branes were then incubated with appropriate primary antibod-
ies (PTGES2, EP4, and GAPDH), followed by incubation
with horse-radish peroxidase-conjugated secondary antibody
(Santa Cruz Biotechnology). The probed proteins were detect-
ed by enhanced chemiluminescent reagents. GAPDH was
used as an internal control.
Immunohistochemistry (IHC)
Staining was performed on paraffin-embedded specimens
using primary antibodies as follows: anti-PTGES2 (1:100;
Proteintech). The percentage of positively stained cells was
rated as follows: 0 point = 0 %, 1 point = 1 % to 25 %, 2
points = 26 % to 50 %, 3 points = 51 % to 75 %, and 4
points=greater than 75 %. The staining intensity was rated
in the following manner: 0 points = negative staining, 1
point =weak intensity, 2 points =moderate intensity, and 3
points = strong intensity. Then, immunoreactivity scores for
each case were obtained by multiplying the values of the
two parameters described above. The average score for all of
five random fields at ×200 magnification was used as the
histological score (HS) as before researches [8]. Tumors were
categorized into two groups based on the HS: low-expression
group (HS<6) and high-expression group (HS≥6). The re-
sults of IHC were analysed with chi-square test.
Cell proliferation
The cell proliferation was examined with the CCK-8 (Cell
Counting Kit-8) assay (Dojindo, Kumamoto, Japan) accord-
ing to the manufacturer’s protocol. After 24, 48, 72, or 96 h of
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incubation, the supernatant of each group was removed, and
cells were incubated in DMEM medium containing CCK-8
for another 2 h at 37 °C. The optical density (OD) value for
each well was read at 450 nm using an automated microplate
reader (Sunrise, Tecan, Switzerland).
Transwell invasion assays
For transwell invasion assays, the upper side of an 8-μm pore,
6.5-mm polycarbonate transwell filter (Corning, New York,
NY) chamber was uniformly coated with Matrigel basement
membrane matrix (BD Biosciences, Bedford, MA) for 2 h at
37 °C before cells were added. A total of 2×104 cells were
seeded into the top chamber of a transwell filter (in triplicate)
and incubated for 48 h. Invasive cells, which were on the
lower side of the filter, were fixed in 4 % paraformaldehyde,
stained in 0.5% crystal violet (Beyotime), and counted using a
microscope. A total of five fields were counted for each
transwell filter. Each field was counted and photographed at
×200 magnification.
Transfection
To inhibit the expression of target gene, we designed and
prepared HPLC-purified siRNAs according to the sequence
of the target gene. A scrambled siRNAwith no homology to
any known human mRNA was used as negative control.
siRNA oligonucleotide duplexes were synthesized by
GenePharma Biotech (Shanghai, China). The sequences of
siRNA oligos are provided in Table 2. Cells were seeded in
6-well plates at 70–80 % confluence and grown overnight
before transfection. Transfection of cells with the siRNA or
non-target control (siCo) was accomplished using the
lipfectamine 2000 transfection reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Enzyme-linked immunosorbent assay (ELISA)
PGE2 levels were detected in culture medium using solid
phase sandwich enzyme-linked immunosorbent assay
(ELISA) assays according to the manufacturer’s protocol
(Cloud-Clone Corp). The PGE2 assay sensitivity was
0.1 pg/ml, and the assay range was 1.03–4000 pg/ml. For
the statistical analysis, culture medium was collected three
times independently.
Statistical analyses
Continuous variables were recorded as mean±SD and ana-
lyzed with the Student’s t test. Data was analyzed by unpaired
Student’s t test or by one-way analysis of variance (ANOVA).
The χ2 test for tables was used to compare the categorical
data. All statistical analyses were done using Statistical
Package for the Social Sciences version 17.0 (SPSS,
Chicago, IL). The P values<0.05were considered statistically
significant. All experiments were performed at least three
times.
Results
PTGES2 is highly expressed in human endometrium
cancer tissues and cell lines
Prostaglandin E synthase 2 (PTGES2) is involved in the syn-
thesis of PGE2. Recent studies have suggested that PGE2may
Table 1 Primer sequences for real-time PCR analysis








Table 2 Expression of PTGES2
in normal endometrium and
endometrial cancer
Groups Patients Histological score (HS) of PTGES2 χ2
low group (HS< 6) High group (HS≥ 6) P
Normal endometrium 50 36 14
Endometrial cancer 119 46 73 <0.001
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be a mitogen associated with a variety of tumors [5–7, 20].We
performed immunohistochemistry (IHC) in normal endome-
trium and endometrial cancer tissues. Compared with the nor-
mal endometrium, the expression of PTGES2 was significant-
ly upregulated in the endometrial cancer tissues (Fig. 1a, b;
Table 2).By statistical analysis, we found that increased ex-
pression of PTGES2 was notably associated with the tumor
stage (P = 0.0088), grade (P = 0.0104), and the depth of
myometrial invasion (P=0.0015), but not with other charac-
teristics (Table 3). We also examined the expression of
PTGES2 in several human endometrial cancer cell lines
(Fig 1c), with protein from normal endometrium (NE) as con-
trol. PTGES2 expression was high in these human endometri-
al cancer cell lines, with the highest levels in Ishikawa cells.
And we chose Ishikawa cells in following research.
Prostaglandin E2 increases proliferation and invasion
potential of human endometrial cancer cells
We initially selected human endometrial cancer cells in which
we performed stable depletion of PTGES2 for subsequent
experiments. To achieve this, we designed three different pairs
shRNAs, and choose the most effective shRNA. As shown in
the representative RT-PCR (Fig 2a) andWestern blot (Fig 2b),
PTGES2 expression was knocked down by shRNA transfec-
tion. We also examined the expressed of PGE2 in PTGES2-
shRNA transfected Ishikawa cells (Fig 2c). As expected,
PGE2 concentration decreased in shPTGE2-Ishikawa cells,
which further confirmed that PTGES2 controls PGE2 synthe-
sis in the cell lines. What is more, we examined PGE2 con-
centration in the control group, C0 group, and PGE2-
stimulated group (Fig 2d). C0 group represent the PGE2
stimulating concentration in culture without cells. Here we
can see that, PGE2 concentration in PGE2 stimulated group
was much higher than control group and C0 group, which
promotes a high concentration of PGE2 can be created with
adding exogenous PGE2 while shPTGES2 creates low PGE2
concentration.We then assessed the proliferation and invasion
of endometrial cancer cells with or without PGE2 stimulation.
A significant increase in proliferation of Ishikawa cells was
observed under PGE2 stimulation (1 × 10−9 mol/L), which
was abolished in shPTGE2-Ishikawa cells (Fig 2e). The
PGE2 concentrations used here were similar as in previously
reported studies [21, 22]. Additionally, PGE2 also increased
the invasion of Ishikawa cells (Fig. 2f), observations that were
significantly inhibited in shPTGE2 Ishikawa cells (Fig 2f).
PGE2 promotes proliferation and invasion via EP4
As there are four different subtypes of the PGE2 receptor, EP1
to EP4, we used three selective EP agonists to determine the
most effective EP. Of the three agonists, sulprostone (Sulp)
bound EP1 and EP3, butaprost (Buta) bound EP2, while pros-
taglandin E1 alcohol (POH) ligated EP4. Fig. 3 shows prolif-
eration and invasion of Ishikawa cells after stimulation with
the three different EP agonists (1×10−9 mol/L). The prolifer-
ation of cells increased in response to POH and was at similar
levels to PGE2, while cells in sulp- and buta-stimulated
groups did not exhibit significant differences in comparison
to control groups (Fig. 3a). We also observed a similar trend in
Fig. 1 PTGES2 expressions in normal endometrium and endometrial
cancer tissues a and b Immunohistochemistry tests for normal
endometrium from curettage patients and cancer tissues from
endometrial cancer patients. c Western blot tests for PTGES2
expression in Ishikawa, Hec-1A, Hec-1B, RL-95-2, and SPEC cells
Table 3 Relationships between PTGES2 expression and
clinicopathologic characteristics in endometrial cancer






Total 119 46 73
Age (years)
≥55 66 21 45 0.0876
<55 53 25 28
FIGO stage





G1–G2 82 38 44 0.0104
G3 37 8 29
Myometrial invasion
≤1/2 69 35 34 0.0015
>1/2 50 11 39
Nodal metastasis
Positive 21 9 12 0.6639
Negative 98 37 61
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the invasion assay, wherein a comparable rate between PGE2
and POHwas seen (Fig. 3b). Subsequent experiments focused
on EP4, and L161982 was chosen as an EP4 antagonist
(10×10−9 mol/L), for rescue experiments. The increased pro-
liferation and invasion rates from PGE2 stimulation were lost
after L161982 treatment (Fig. 3c, d). As the result, EP4 was
considered to be the modulating EP in the PGE2-induced
effect on proliferation and invasion of human endometrial
cancer cells.
PGE2 promotes endometrial cancer cell proliferation
and invasion by stimulating SUMO-1
To determine the downstream target of EP4, we analyzed the
SUMOs in PGE2-stimulated Ishikawa cells. Some before re-
searches had showed SUMOs act an important role in onco-
genesis and human endometrium proliferation [23–25], and
SUMOylation had potential connect with COX and PGE2 in
gynecology tumors such as ovarian cancers [26]. The mRNA
of SUMO-1 was increased in PGE2-stimulated group while
SUMO-2 and SUMO-3 showed no obvious changes (Fig 4a),
results that were confirmed by Western blot analysis (Fig 4b).
To further examine the role of SUMO-1 in PGE2-induced
proliferation and invasion, three SUMO-1 siRNA primer pairs
were designed and the most effective siRNAwas used in fur-
ther experiments, whose transfection efficiency was con-
firmed by mRNA and protein level analyses (Fig 4c). The
results of CCK-8 and transwell assays showed that SUMO-1
could promote proliferation and invasion in endometrial can-
cer cells (Fig 4d). To further assess the signaling pathway
involved in the interaction of EP4 and SUMO-1, Ishikawa
cells were treated with three different signal inhibitors,
AZD5363 (Akt inhibitor, 1×10−6 mol/L), FH535 (β-catenin
inhibitor, 1.5×10−6 mol/L) and ICI (estrogen receptor antag-
onist, 1×10−6 mol/L), and we examined the gene expression
of SUMO-1 (Fig 4e). The results showed that SUMO-1
mRNA expression was inhibited by FH535 treatment, which
suggested that the Wnt/β-catenin signaling pathway was the
mediator for EP4 and SUMO-1.We further examined SUMO-
1 protein levels with Western blot (Fig 4f) to confirm the role
of Wnt/β-catenin signaling pathway in cells. Finally, the re-
sults of CCK-8 and transwell analyses showed that SUMO-1
can promote proliferation and invasion in endometrial cancer
cells through Wnt/β-catenin signaling pathway (Fig 4g).
Fig. 2 Prostaglandin E2 raises proliferation and invasion in human
endometrial cancer cells a RT-PCR analysis for Ishikawa cells after
transfection of PTGES2 shRNAs. *p< 0.05 versus control group, tested
with unpaired Student’s t test. bWestern blot tests for Ishikawa cells after
transfection of PTGES2 shRNAs. c ELISA for PGE2 concentration in
shRNAs transfected Ishikawa cells after 24 h of culture. *p < 0.05,
analyzed by one-way analysis of variance (ANOVA). d ELISA for
PGE2 concentration in PGE2 stimulated Ishikawa cells after 24 h of
culture. C replicated control group, in which no PGE2 stimulated. C0
replicated PGE2 working concentration. *p < 0.05, analyzed by one-
way analysis of variance (ANOVA). e CCK8 assays were conducted at
each time point to quantify cell viability for Ishikawa cells transfected
with control or PTGES2 shRNA, or stimulated with PGE2. *p< 0.05,
analyzed by one-way analysis of variance (ANOVA). f Transwell for
Ishikawa cells with PGE2 stimulated or transfected with PTGES2
shRNA. Figure shows the number of invasive cells for each group
(averaged across five random images). **p < 0.01, analyzed by one-
way analysis of variance (ANOVA)
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Discussion
The mediators and cellular effectors of inflammation are im-
portant constituents of the local tumor microenvironment [27].
Tumor-promoting inflammation is an accepted enabling char-
acteristic of cancers [28]. Some recent studies have shown the
relationship between cancers and inflammatory factors, such
as IL-6 [8] and IL-10 [29]. As a classical cytokine, prostaglan-
din was first identified in 1936 [30]. A series of studies of
prostaglandin in cancers showed that the subtype of EPs effect
in different cancers was variable [5, 6, 31]. A recent study
showed that PGE2 induces lung metastasis in breast cancers
via EP2 [32]. However, in endometrial cancers, no result of
PGE2 functional activation has ever been reported. Our work
uncovered that PGE2 promotes the proliferation and invasion
of endometrial cancer cells via its receptor subtype, EP4.
Based on our results, we examined two points in the mecha-
nism: EP4 and SUMO-1. In this mechanism, EP4 act as a gate
of the effect while high PGE2 concentration of tumor micro-
environment influences the outcome of endometrial cancer
cells.
In our study, first we showed that PTGES2 is highly
expressed in endometrial cancer both in tissue and in cell lines.
Further experiments uncovered EP4 as the key receptor in the
PGE2 effect which influenced endometrial cancer cells prolifer-
ation and invasion. In previous studies, PGE2 was thought to
play an important role in most gynecological tumors via differ-
ent receptors [7, 33]. However, EP2 does not effect these chang-
es, which was not the same as some previous studies in many
other cancers [10, 11, 34]. This suggested that a new therapeutic
opportunity might exist for patients with endometrial cancers
and prevention for those in high-risk groups. In 2005,
Francesmary Modugno et al. recommended that inflammation
may work in conjunction with, or in addition to, estrogen expo-
sure in the development of endometrial cancer [35]. Some recent
clinical researches also showed that the use of aspirin, but not
non-aspirin NSAIDs, may reduce the risk of endometrial cancer
[36]. However, as is known, NSAIDs increase gastrointestinal
discomfort and may aggravate illness in ulcer patients. EP4may
therefore be a new target for further treatment with fewer side
effects in both treatment and prevention.
Another keypoint of themechanism inour studywasSUMO-
1, whose expression was promoted by PGE2, and further en-
hancedproliferationand invasion.As isknown,SUMOscontrib-
ute to protein modification, especially in transcription, chromo-
some organization, and DNA repair [37]. A recent study
Fig. 3 PGE2 raises proliferation and invasion via EP4 a CCK8 assays
were conducted at each time point to quantify cell viability for Ishikawa
cells transfected after clutching with three EP agonists. **p < 0.01,
analyzed by one-way analysis of variance (ANOVA). b Transwell for
Ishikawa cells after clutching with three EP agonists. Figure shows the
number of invasive cells for each group (averaged across five random
images). *p< 0.05, **p< 0.01, analyzed by one-way analysis of variance
(ANOVA). c CCK8 assays were conducted at each time point to quantify
cell viability for Ishikawa cells transfected after treated with EP4
antagonist L161982, together with or without PGE2 and POH.
*p < 0.05, analyzed by one-way analysis of variance (ANOVA). d
Transwell for Ishikawa cells after adding EP4 antagonist L161982,
treated with or without PGE2 and POH. Figure shows the number of
invasive cells for each group (averaged across five random images)
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suggested that SUMO-1 promotes cancer cells proliferation and
apoptosis by increasing SUMOylation of histone H4 [38]. This
research demonstrated the importance of histone modification,
which conclusion motivated our study. In 2012, Picard et al. de-
termined that estrogen receptor β was a SUMOylation target of
SUMO-1[39].Wehaveknown the relationshipbetweenestrogen
and endometrial cancer and their consequence points to SUMO-
1, and likely integrates several exogenous cytokine signals. A
study from Oxford showed that chromatin modification by
SUMO-1 stimulates the promoters of translation machinery
genes [40]. In addition to gene expression, the changes of cancer
cell metabolism in hypoxia environment are also related to
SUMO-1 function of [41]. All these studies demonstrated that
SUMO-1 is an important point in oncogenesis, and the down-
stream targets of SUMO-1 are flexible andworth further studies.
We discovered that Wnt/β catenin signaling pathway acts an
important role between EP4 and SUMO-1. As is known, the
Wnt signaling pathway is closely related with many human
diseases such as colorectal cancer [42] and glioblastoma [43].
Wnt signaling has also been examined in endometrial cancers.
Some recent studies had reported that Wnt pathway inhibitors
expression was down-regulated in cancer patients [44]. We find
β-catenin expression reduced after inhibition of EP4, and
SUMO-1 expression reduced upon inhibition of β-catenin.
However,Wnt/β-catenin signaling pathwaymay not be the only
signal pathway in EP4 regulation to SUMO-1. In our study,
while we examined three major signal pathways, this is not
exhaustive and we therefore cannot rule out other unexamined
pathways that may contribute to EP4 regulation to SUMO-1.
Future studies should explore these additional pathways.
Fig. 4 PGE2 promotes endometrial cancer cell proliferation and invasion
by stimulates SUMO-1 a RT-PCR analysis for three SUMO subtypes in
Ishikawa cells after PGE2 stimulated. *p< 0.05, analyzed by one-way
analysis of variance (ANOVA). b Western blot tests for three SUMO
subtypes in Ishikawa cells after PGE2 stimulated. c RT-PCR analysis
and western blot tests in Ishikawa cells after transfected with SUMO-1
siRNAs. *p< 0.05 versus control group, tested with unpaired Student’s t
test. d CCK8 assays were conducted at each time point to quantify cell
viability for Ishikawa cells after transfection of SUMO-1 siRNAs.
*p < 0.05, analyzed by one-way analysis of variance (ANOVA). e
Ishikawa cells were treated with AZD5363 (1 × 10–6 mol/L), FH535
(1.5 × 10–6 mol/L), and ICI (1 × 10−6 mol/L) for 24 h. Then stimulated
with PGE2, POH, or L161982. RT-PCR analysis for SUMO-1 in
Ishikawa cells. *p < 0.05, analyzed by one-way analysis of variance
(ANOVA). f Ishikawa cells were treated with FH535 (1.5 × 10–6 mol/L)
or L161982 (10 × 10–9 mol/L) for 24 h, then stimulated with or without
PGE2. Western blot tests for β-catenin and SUMO-1 in Ishikawa cells. g
CCK8 assays were conducted at each time point to quantify cell viability
for Ishikawa cells treated with PGE2 (1 × 10–9 mol/L), FH535 (1.5 × 10–
6 mol/L), or L161982 (10 × 10–9 mol/L). Transwell for Ishikawa cells
treated with PGE2 (1 × 10–9 mol/L), FH535 (1.5 × 10–6 mol/L) or
L161982 (10 × 10−9 mol/L). Figure shows the number of invasive cells
for each group (averaged across five random images). *p < 0.05, analyzed
by one-way analysis of variance (ANOVA)
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In summary,we demonstrated a likelymechanismof prolifer-
ation and invasion in endometrial cancer cells. PGE2 promoted




endometrial cancers. These findings also suggest that inflamma-
tion in tumor microenvironment and protein modifications con-
siderably contribute to tumorigenesis and development.
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